Qingdao Haier Biomedical Co.,Ltd (SHA:688139)
China
· Delayed Price · Currency is CNY 31.65
+0.55 (1.77%)
Mar 6, 2026, 4:00 PM EST
SHA:688139 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,329 | 2,274 | 2,272 | 2,855 | 2,119 | Upgrade
|
| Other Revenue | - | 9.85 | 9.24 | 8.62 | 7.31 | Upgrade
|
| Revenue | 2,329 | 2,284 | 2,281 | 2,864 | 2,126 | Upgrade
|
| Revenue Growth (YoY) | 1.96% | 0.13% | -20.36% | 34.72% | 51.63% | Upgrade
|
| Cost of Revenue | - | 1,190 | 1,174 | 1,490 | 1,061 | Upgrade
|
| Gross Profit | 2,329 | 1,094 | 1,107 | 1,374 | 1,065 | Upgrade
|
| Selling, General & Admin | - | 471.73 | 476.68 | 513.72 | 388.03 | Upgrade
|
| Research & Development | - | 306.17 | 320.64 | 292.47 | 236.31 | Upgrade
|
| Other Operating Expenses | 2,062 | -6.48 | -7.25 | 2.34 | 1.63 | Upgrade
|
| Operating Expenses | 2,062 | 787.08 | 793.97 | 809.08 | 622.71 | Upgrade
|
| Operating Income | 266.34 | 306.58 | 312.95 | 564.67 | 441.98 | Upgrade
|
| Interest Expense | - | -3.41 | -3.51 | -2.69 | -2.89 | Upgrade
|
| Interest & Investment Income | - | 71.46 | 118.64 | 95.02 | 483.95 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.46 | -7.72 | 3.58 | 4.14 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.58 | -1.83 | -1.68 | -1.49 | 0.56 | Upgrade
|
| EBT Excluding Unusual Items | 264.76 | 377.25 | 418.67 | 659.1 | 927.74 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 5.47 | 2.06 | -7.01 | 10.21 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.23 | -1.6 | -0.76 | -0.52 | Upgrade
|
| Asset Writedown | - | -1.86 | -2.36 | - | - | Upgrade
|
| Other Unusual Items | - | 20.87 | 17.72 | 24 | 23.44 | Upgrade
|
| Pretax Income | 264.76 | 401.96 | 434.49 | 675.34 | 960.87 | Upgrade
|
| Income Tax Expense | 14.03 | 20.95 | 22.43 | 63.36 | 111.7 | Upgrade
|
| Earnings From Continuing Operations | 250.73 | 381.01 | 412.06 | 611.97 | 849.17 | Upgrade
|
| Minority Interest in Earnings | - | -14.38 | -5.99 | -11.18 | -4.14 | Upgrade
|
| Net Income | 250.73 | 366.63 | 406.07 | 600.79 | 845.04 | Upgrade
|
| Net Income to Common | 250.73 | 366.63 | 406.07 | 600.79 | 845.04 | Upgrade
|
| Net Income Growth | -31.61% | -9.71% | -32.41% | -28.90% | 121.82% | Upgrade
|
| Shares Outstanding (Basic) | 313 | 316 | 317 | 318 | 316 | Upgrade
|
| Shares Outstanding (Diluted) | 313 | 316 | 317 | 318 | 318 | Upgrade
|
| Shares Change (YoY) | -0.84% | -0.37% | -0.20% | 0.06% | -2.43% | Upgrade
|
| EPS (Basic) | 0.80 | 1.16 | 1.28 | 1.89 | 2.67 | Upgrade
|
| EPS (Diluted) | 0.80 | 1.16 | 1.28 | 1.89 | 2.66 | Upgrade
|
| EPS Growth | -31.03% | -9.38% | -32.27% | -28.95% | 127.35% | Upgrade
|
| Free Cash Flow | - | 164.96 | 72.08 | 338.18 | 387.11 | Upgrade
|
| Free Cash Flow Per Share | - | 0.52 | 0.23 | 1.06 | 1.22 | Upgrade
|
| Dividend Per Share | - | 0.470 | 0.515 | 0.450 | 0.500 | Upgrade
|
| Dividend Growth | - | -8.74% | 14.44% | -10.02% | 31.61% | Upgrade
|
| Gross Margin | 100.00% | 47.89% | 48.53% | 47.97% | 50.08% | Upgrade
|
| Operating Margin | 11.44% | 13.42% | 13.72% | 19.72% | 20.79% | Upgrade
|
| Profit Margin | 10.77% | 16.05% | 17.80% | 20.98% | 39.75% | Upgrade
|
| Free Cash Flow Margin | - | 7.22% | 3.16% | 11.81% | 18.21% | Upgrade
|
| EBITDA | 371.14 | 411.38 | 410.67 | 626.73 | 491.15 | Upgrade
|
| EBITDA Margin | 15.94% | 18.01% | 18.00% | 21.88% | 23.10% | Upgrade
|
| D&A For EBITDA | 104.8 | 104.8 | 97.72 | 62.06 | 49.17 | Upgrade
|
| EBIT | 266.34 | 306.58 | 312.95 | 564.67 | 441.98 | Upgrade
|
| EBIT Margin | 11.44% | 13.42% | 13.72% | 19.72% | 20.79% | Upgrade
|
| Effective Tax Rate | 5.30% | 5.21% | 5.16% | 9.38% | 11.63% | Upgrade
|
| Revenue as Reported | - | 2,284 | 2,281 | 2,864 | 2,126 | Upgrade
|
| Advertising Expenses | - | 24.88 | 31.82 | 25.41 | 14.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.